CA2341253A1 - Inhibiteurs de telomerase et leurs procedes d'utilisation - Google Patents

Inhibiteurs de telomerase et leurs procedes d'utilisation Download PDF

Info

Publication number
CA2341253A1
CA2341253A1 CA002341253A CA2341253A CA2341253A1 CA 2341253 A1 CA2341253 A1 CA 2341253A1 CA 002341253 A CA002341253 A CA 002341253A CA 2341253 A CA2341253 A CA 2341253A CA 2341253 A1 CA2341253 A1 CA 2341253A1
Authority
CA
Canada
Prior art keywords
compound
mmol
composition
dione
thiazolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002341253A
Other languages
English (en)
Inventor
Allison C. Chin
Ryan Holcomb
Mieczyslaw A. Piatyszek
Upinder Singh
Richard L. Tolman
Tsutomu Akama
Yutaka Kanda
Akira Asai
Yoshinori Yamashita
Kaori Endo
Hiroyuki Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Geron Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP30757699A external-priority patent/JP2001072592A/ja
Application filed by Individual filed Critical Individual
Publication of CA2341253A1 publication Critical patent/CA2341253A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

L'invention porte sur des composés de thiazolidinedione, sur des compositions, et sur des procédés d'inhibition de l'activité de la télomérase <i>in vitro</i> et sur le traitement des états ou maladies induits par la télomérase <i>ex vivo</i> et <i>in vivo</i>. Les procédés, composés et compositions de l'invention peuvent être utilisés seuls, ou en combinaison avec d'autres agents actifs d'un point de vue pharmacologique dans le traitement d'états ou maladies induits par l'activité de la télomérase, par exemple dans les traitements anticancéreux. L'invention porte également sur de nouvelles méthodes de dosage ou recherche systématique des inhibiteurs de l'activité de la télomérase.
CA002341253A 1999-07-01 2000-06-30 Inhibiteurs de telomerase et leurs procedes d'utilisation Abandoned CA2341253A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14217399P 1999-07-01 1999-07-01
JP11/187616 1999-07-01
US60/142,173 1999-07-01
JP18761699 1999-07-01
JP11/307576 1999-10-28
JP30757699A JP2001072592A (ja) 1999-07-01 1999-10-28 テロメラーゼ阻害剤
PCT/US2000/018211 WO2001002377A1 (fr) 1999-07-01 2000-06-30 Inhibiteurs de telomerase et leurs procedes d'utilisation

Publications (1)

Publication Number Publication Date
CA2341253A1 true CA2341253A1 (fr) 2001-01-11

Family

ID=27325921

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341253A Abandoned CA2341253A1 (fr) 1999-07-01 2000-06-30 Inhibiteurs de telomerase et leurs procedes d'utilisation

Country Status (9)

Country Link
EP (1) EP1109796A1 (fr)
JP (1) JP2003507473A (fr)
KR (1) KR20010099634A (fr)
CN (1) CN1321153A (fr)
AU (1) AU6340600A (fr)
CA (1) CA2341253A1 (fr)
HK (1) HK1043113A1 (fr)
ID (1) ID29875A (fr)
WO (1) WO2001002377A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217511A (zh) * 2023-03-22 2023-06-06 沈阳药科大学 一种双靶点化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007423A1 (fr) * 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Compositions medicamenteuses possedant une activite agoniste de la thrombopoietine
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
ATE310733T1 (de) * 2000-04-21 2005-12-15 Pfizer Prod Inc Thyroid-rezeptorliganden
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
AU2001259130A1 (en) * 2000-04-24 2001-11-07 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
AU2001294673A1 (en) 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
WO2003018011A1 (fr) 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-(substitue)-5-(substitue sulfonyl ou sulfanyl)thiazolidine-2,4-diones utiles pour l'inhibition de la farnesyl-proteine transferase
US7045523B2 (en) 2001-10-18 2006-05-16 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
GB0204252D0 (en) * 2002-02-23 2002-04-10 Oxford Glycosciences Uk Ltd Novel compounds
EP1551396A1 (fr) * 2002-09-26 2005-07-13 Pintex Pharmaceuticals, Inc. Composes de modulation de pin-1 et leurs procedes d'utilisation
US6794401B2 (en) 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7521465B2 (en) 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7781464B2 (en) 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
WO2004093803A2 (fr) * 2003-04-16 2004-11-04 Pintex Pharmaceuticals, Inc. Composes photochimiotherapeutiques utilises dans le traitement d'etats associes a pin1
US7087576B2 (en) 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
FI20041129A0 (fi) * 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
BRPI0516219A (pt) 2004-09-28 2008-08-26 Otsuka Pharma Co Ltd composto de carboestirila
FR2887444A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite.
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
TWI315304B (en) * 2006-08-31 2009-10-01 Univ Taipei Medical Indoline-sulfonamides compounds
ES2377165T3 (es) * 2007-03-07 2012-03-23 Janssen Pharmaceutica N.V. Tiazolidinediona N-alquilada fenoxi-sustituida como moduladores del receptor de estrógenos alfa
CA2743756A1 (fr) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibiteurs de proteines kinases pim, compositions et procedes pour traiter le cancer
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
CN101973893B (zh) * 2010-09-07 2013-07-17 黑龙江省科学院石油化学研究院 4-[2-(1-苯乙烯基)]-n,n-二(4-溴苯基)苯胺的合成方法
KR101817287B1 (ko) 2016-01-08 2018-01-10 조선대학교 산학협력단 티아졸리딘디온 유도체 및 그의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4738972A (en) * 1985-05-21 1988-04-19 Pfizer Inc. Hypoglycemic thiazolidinediones
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (fr) * 1988-03-08 1989-09-21 Pfizer Inc. Derives de thiaxolidinedione hypoglycemiques
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5143929A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217511A (zh) * 2023-03-22 2023-06-06 沈阳药科大学 一种双靶点化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用
CN116217511B (zh) * 2023-03-22 2024-04-19 沈阳药科大学 一种双靶点化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用

Also Published As

Publication number Publication date
EP1109796A1 (fr) 2001-06-27
AU6340600A (en) 2001-01-22
KR20010099634A (ko) 2001-11-09
HK1043113A1 (zh) 2002-09-06
CN1321153A (zh) 2001-11-07
WO2001002377A1 (fr) 2001-01-11
WO2001002377A9 (fr) 2001-10-11
JP2003507473A (ja) 2003-02-25
ID29875A (id) 2001-10-18

Similar Documents

Publication Publication Date Title
US6518268B1 (en) Telomerase inhibitors and methods of their use
CA2341253A1 (fr) Inhibiteurs de telomerase et leurs procedes d&#39;utilisation
US5863936A (en) Telomerase inhibitors
US5767278A (en) Telomerase inhibitors
US5656638A (en) Telomerase inhibitors
US5760062A (en) Telomerase inhibitors
EP0149884B1 (fr) Dérivés de 5-pyridyle-1,3-thiazole, leur préparation et utilisation
US6452014B1 (en) Telomerase inhibitors and methods of their use
US5770613A (en) Telomerase inhibitors
US5703116A (en) Telomerase Inhibitors
WO1992009279A1 (fr) Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive
JP2003155274A (ja) 置換されたインドールアルカノール酸
EP2875010B1 (fr) Derives de thiophenes utiles dans le traitement du diabete
CA2408448A1 (fr) Indazoles substitues avec de la 1,1-dioxoisothiazolidine utiles comme inhibiteurs de la proliferation cellulaire
US7329682B2 (en) Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
JPH09188677A (ja) 医薬有効物質としての置換されたイミダゾリジン− ２，４− ジオン− 化合物
JPH04503212A (ja) ５―リポキシゲナーゼ阻止剤としての４―ヒドロキシチアゾール
US6372742B1 (en) Substituted indole compounds and methods of their use
JP4395073B2 (ja) キナゾリン−４−オン誘導体
WO1999065875A1 (fr) Inhibiteurs de la telomerase
GB2387172A (en) [(Aryl-/arylthio-)aryl]methylene substituted azole &amp; azine derivatives and their therapeutic use as antibacterials
US7563905B2 (en) Triazole derivatives and method of using the same to treat HIV infections
CN109574920A (zh) 3-腈基-6环丙基吡啶类ido1抑制剂及其用途
CN102086212A (zh) 抗真菌剂-2，3，4，5-四氢-4H-苯并[b]噻喃并[4，3-c]吡唑-2-甲酰胺衍生物
US9290484B2 (en) Furyl and thienyl triazole derivatives and therapeutic uses thereof

Legal Events

Date Code Title Description
FZDE Dead